Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Spinal Cord Injury
NCT ID: NCT01135108
Last Updated: 2025-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
5 participants
INTERVENTIONAL
2009-03-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia
NCT01106716
Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy Volunteers
NCT04110886
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
NCT06438471
Ketamine HCl Prolonged Release Oral Tablets for CRPS
NCT06419985
Chronic Pain in Spinal Cord Injury
NCT00006428
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A1: Placebo
Placebo
Placebo
Placebo IV Infusion
A2: KAI-1678
Experimental
KAI-1678
KAI-1678 IV Infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo IV Infusion
KAI-1678
KAI-1678 IV Infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* central neuropathic pain for at least 3 months or with relapses and remissions for at least 6 months
* pain score at least 4 on 11-point numerical rating scale (0-10)
* stable doses of analgesic medications for at least 1 month
Exclusion Criteria
* tolerance to opioid analgesics
* clinically significant abnormality on laboratory tests or ECG
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Trident Clinical Research Pty Ltd
INDUSTRY
KAI Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregory Bell, MD
Role: STUDY_DIRECTOR
KAI Pharmaceuticals, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sydney, New South Wales, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KAI-1678-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.